 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

PHILADELPHIA, Nov. 21, 2023 (GLOBE NEWSWIRE) -- Century Therapeutics (NASDAQ: IPSC), an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in...

Century Therapeutics to Present at the Piper Sandler 35th Annual Healthcare Conference

Piper Sandler analyst Edward Tenthoff reiterated a Buy rating on Century Therapeutics (IPSC Research Report) today and set a price target of $10...

Piper Sandler Sticks to Their Buy Rating for Century Therapeutics (IPSC)

- Brent Pfeiffenberger, Pharm.D., MBA, appointed Chief Executive Officer of Century Therapeutics - - Initial data from the ongoing Phase 1 ELiPSE-1 trial evaluating CNTY-101 in relapsed or...

Century Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Updates

PHILADELPHIA and MADISON, Wis., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Century Therapeutics, Inc. (NASDAQ: IPSC), an innovative clinical-stage biotechnology company developing induced pluripotent stem...

Century Therapeutics and FUJIFILM Cellular Dynamics Announce Licenses for the Development and Commercialization of iPSC-Derived Cell Therapies in Autoimmune and Inflammatory Diseases

Brent Pfeiffenberger, Pharm.D., MBA

 Brent Pfeiffenberger, Pharm.D., MBA

- Accomplished leader with over 20 years of broad-ranging experience across the healthcare industry...

Century Therapeutics Appoints Brent Pfeiffenberger, Pharm.D., MBA, as Chief Executive Officer

Financial Performance and Strategic Developments in FocusRelated Stocks: IPSC...

Century Therapeutics Inc (IPSC) Reports Q3 2023 Financial Results

See the rest of the story here.

thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...

Century Therapeutics to present data from Phase 1 ELiPSE-1 trial of CNTY-101

CNTY-101 is the first cell therapy product candidate engineered with six precision gene edits including a CD19-CAR, Allo-Evasion technology, IL-15 cytokine support, and a safety switch...

Century Therapeutics to Present Initial Clinical Data Supporting the Potential for a Multi-Dosing Strategy for CAR iNK Enabled by Allo-Evasion  Edits at the 65th ASH Annual Meeting and Exposition

Century Therapeutics, Inc. (NASDAQ:IPSC  Free Report)  Equities researchers at Leerink Partnrs lowered their Q3 2023 EPS estimates for Century Therapeutics in a report issued on...

Q3 2023 EPS Estimates for Century Therapeutics, Inc. (NASDAQ:IPSC) Cut by Analyst

PHILADELPHIA, Sept. 26, 2023 (GLOBE NEWSWIRE) -- Century Therapeutics (NASDAQ: IPSC), an innovative clinical-stage biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell...

Century Therapeutics to Present at the Chardan 7th Annual Genetic Medicines Conference

Century Therapeutics, Inc. engages in the development of off-the-shelf cell therapies to advance the course of cancer care. It focuses on harnessing the power of adult stem cells to develop curative allogeneic cell therapies for cancer. The company was founded by Marcela Maus and Hiromitsu Nakauchi in 2018 and is headquartered in Philadelphia, PA.

Watchers	260
52-Wk Low	$1.28
52-Wk High	$10.95

Market Cap	$87.36M
Volume (M)	101,105.00
52-Wk High	$10.95
52-Wk Low	$1.28

IPSC Century Therapeutics Inc

About

Feed

News

Sentiment

Earnings

Fundamentals

Sentiment

Message Volume

Community